Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2?3 randomised trial. Lancet Gastroenterology and Hepatology 3 (3), pp. 162-171. 10.1016/S2468-1253(17)30394-1

Please note:
Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher’s version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.
Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial

Richard Adams, Ewan Brown, Louise Brown, Rachel Butler, Stephen Falk, David Fisher, Richard Kaplan, Phil Quirke, Susan Richman, Leslie Samuel, Jenny Seligmann, Matt Seymour, Kai Keen Shiu, Harpreet Wasan, Richard Wilson, Tim Maughan, on behalf of the FOCUS4 Trial Investigators

Summary

Background A substantial change in trial methodology for solid tumours has taken place, in response to increased understanding of cancer biology. FOCUS4 is a phase 2–3 trial programme testing targeted agents in patients with colorectal cancer in molecularly stratified cohorts. Here, we aimed to test the hypothesis that combined inhibition of EGFR, HER2, and HER3 signalling with the tyrosine kinase inhibitor AZD8931 will control growth of all wild-type tumours.

Methods In FOCUS4-D, we included patients from 18 hospitals in the UK with newly diagnosed advanced or metastatic colorectal cancer whose tumour was wild-type for BRAF, PIK3CA, KRAS, and NRAS. After 16 weeks of first-line therapy, patients with stable or responding tumours were randomised to oral AZD8931 (40 mg twice a day) or placebo. Randomisation was done with a random element of 20%, minimisation by hospital site, site of primary tumour, WHO performance status, 16-week CT scan result, number of metastatic sites, and first-line chemotherapy regimen. The primary outcome was progression-free-survival. CT scans were assessed by local radiologists according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. Preplanned interim analyses were assessed per protocol and were agreed using multiarm multistage (MAMS) trial design methodology triggered by occurrence of progression-free survival events in the placebo group. The final analysis was assessed by intention to treat. This trial is registered at controlled-trials.com, ISRCTN 90061546.

Findings Between July 7, 2014, and March 7, 2016, 32 patients were randomised to study treatment, 16 to AZD8931 and 16 to placebo. At the first preplanned interim analysis (March, 2016), the independent data monitoring committee (IDMC) recommended closure of FOCUS4-D because of a lack of activity. At the final analysis (Aug 1, 2016), 31 patients had had a progression-free survival event (15 with AZD8931 and 16 with placebo). Median progression-free survival was 3·48 months (95% CI 1·51–5·09) in the placebo group and 2·96 months (1·94–5·62) in the AZD8931 group. No progression-free survival benefit of AZD8931 compared with placebo was noted (hazard ratio [HR] 1·10, 95% CI 0·47–3·57; p=0·95). The most common grade 3 adverse event in the AZD8931 group was skin rash (three [20%] of 15 patients with available data vs none of 16 patients in the placebo group), and in the placebo group it was diarrhoea (one [7%] vs one [6%]). No grade 4 adverse events were recorded and no treatment-related deaths were reported.

Interpretation The MAMS trial design for FOCUS4 has shown efficiency and effectiveness in trial outcome delivery, informing the decision to proceed or stop clinical evaluation of a targeted treatment within a molecularly defined cohort of patients. The overarching FOCUS4 trial is now aiming to open a replacement arm in the cohort with all wild-type tumours.

Funding Medical Research Council (MRC) and National Institute for Health Research (NIHR) Efficacy and Mechanism Evaluation programme, Cancer Research UK, NIHR Clinical Trials Research Network, Health and Care Research Wales, and AstraZeneca.

Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
benefit for most of these biomarker-selected patients, thus driving interest in novel approaches to inhibit this pathway. However, EGFR remains a valid target in colorectal cancer within the population of patients wild-type for KRAS, NRAS, and BRAF, with proven clinical benefit.

The proteins HER2 and HER3 (also known as ERBB2 and ERBB3, respectively) heterodimerise with EGFR and are mechanisms of resistance to EGFR inhibition. HER3 is a membrane-bound receptor protein that has extracellular heresulin and neuregulin binding domains but does not have an intracellular kinase domain, relying on heterodimerisation to other family members for downstream effects. HER3 expression is associated with poor prognosis in colorectal cancer. The protein has a central role in driving oncogenic signals in tumours, and preclinical and clinical data have led to the hypothesis that HER3 is an escape pathway to EGFR blockade. HER2 is an orphan receptor, having no known associated ligands, but is activated through homodimerism and heterodimerisation with other EGFR family members, resulting in intracellular phosphorylation and cascaded downstream signalling. Growing in-vitro and in-vivo evidence suggests that HER2 might be overexpressed more frequently in patients with EGFR-dependent (all wild-type) tumours. Furthermore, this protein might be upregulated in acquired EGFR inhibitor resistance, and concomitant blockade of HER2 could increase efficacy and prolong activity in a synergistic fashion. Bertotti and colleagues developed a range of colorectal cancer xenograft models from genetically well-characterised, metastatic colorectal cancer samples. A cohort of these so-called xenopatients showed amplification of HER2, particularly in RAS wild-type tumours, suggesting enrichment in this cohort, which showed high and sustained sensitivity to combination EGFR and HER2 inhibition. Inhibition of EGFR, HER2, and HER3 signalling is postulated to reduce de-novo resistance, thereby increasing the proportion of patients showing benefit when compared with inhibition of EGFR only. Furthermore, this inhibition might slow the development of acquired resistance in patients with initially EGFR-dependent tumours, therefore providing greater clinical benefit than EGFR inhibition alone.

The convergence of the molecular understanding of colorectal cancer and clinical development of a wide range of targeted treatments demands evaluation of new agents within biologically defined subsets of patients whose tumours are most likely to benefit. Moreover, after the failure of many trials to show benefit for a new treatment in colorectal cancer, we clearly need a new paradigm to attempt to make progress. The idea of one research question for all patients is outdated in colorectal cancer and clinical development of a wide range of targeted treatments demands evaluation of new combination strategy for breast cancer, no efficacy was recorded.

**Research in context**

**Evidence before this study**
The HER family has been a focus of attention in colorectal cancer since the development and licensing of the EGFR monoclonal antibodies panitumumab and cetuximab. The mechanism of action of these agents remains to be elucidated fully but has led to preclinical research implicating other HER family members in de-novo or evolving resistance. Several molecules (both monoclonal antibodies and tyrosine kinase inhibitors) have been developed that aim to overcome resistance pathways in selected patients. The most successful of these approaches to date has been a combination of trastuzumab and lapatinib, which has shown efficacy in a small cohort of patients with metastatic colorectal cancer harbouring HER2-positive tumours. All other drugs that have been developed specifically to interact with the HER family have so far failed to show additional efficacy in colorectal cancer, above that evident for cetuximab or panitumumab. AZD8931 was designed to inhibit EGFR, HER2, and HER3 signalling. In two previous trials of AZD8931 as part of a multistage (MAMS) study design allowed optimisation of recruitment and early assessment of the drug in an efficient and effective manner.

**Added value of this study**
Our study is the first randomised controlled trial to investigate use of AZD8931 in patients with colorectal cancer and in a prespecified molecular cohort of patients deemed most likely to be responsive to this approach. The multiarm multistage (MAMS) study design allowed optimisation of recruitment and early assessment of the drug in an efficient and effective manner.

**Implications of the available evidence**
AZD8931 showed no benefit in the first-line setting for metastatic colorectal cancer. The finding that this agent was ineffective in a molecularly defined subgroup of patients suggests that as monotherapy, AZD8931 has little to add in this disease type. The MAMS trial design has shown an ability to deliver an efficient and effective trial in molecularly defined cohorts of patients with metastatic colorectal cancer.
the biomarker-defined groups.29 Such a trial design fulfils the pressing need to deliver molecularly driven interventions to appropriately defined cohorts of patients in an efficient and effective fashion. The FOCUS4 programme of trials investigates such a design in patients with advanced colorectal cancer.

FOCUS4 was set up to provide a trial platform for rapid identification of patients whose tumours can be characterised either by the presence of specific mutations or by validated biomarkers that characterise biological cohorts. The trial uses an adaptive design that allows early preplanned interim analyses of molecular cohorts to review whether there is sufficient drug activity to justify continuing the trial being undertaken in that cohort.11 Clinical trials are costly, and prudent direction of resources towards drugs that look the most promising could improve the efficiency with which new drugs can be evaluated. In this Article, we report the findings of one of these molecular cohorts (FOCUS4-D), which reached its first interim analysis trigger point in March, 2016. The aim of FOCUS4-D was to test the efficacy of AZD8931 in patients with colorectal cancer whose tumours are wild-type for \( \text{BRAF} \), \( \text{PIK3CA} \), \( \text{KRAS} \), and \( \text{NRAS} \) mutations.

AZD8931 is an orally active, equipotent tyrosine kinase inhibitor of EGFR, HER2, and HER3 signalling. In-vitro analysis of AZD8931 in ligand-driven cell assays shows potency exceeding that of gefitinib and lapatinib in this system for EGFR, HER2, and HER3 inhibition.12 In pharmacokinetic and dynamic analyses, a direct relation was recorded between the total amount of AZD8931 in plasma and inhibition of EGFR phosphorylation.12 Within FOCUS4-D, we excluded patients with PTEN loss or somatic \( \text{BRAF} \), \( \text{PIK3CA} \), \( \text{KRAS} \), and \( \text{NRAS} \) mutations. The rationale for the exclusion of patients with \( \text{BRAF} \) mutations relates to two specific sets of data. First, \( \text{BRAF} \)-mutant colorectal cancer has significantly worse prognosis than does disease with wild-type \( \text{KRAS} \) and \( \text{NRAS} \).13 Second, despite some conflicting evidence, \( \text{BRAF} \)-mutant tumours gain no additional benefit from targeted EGFR inhibition.14 Patients harbouring tumours with a \( \text{PIK3CA} \) mutation or PTEN loss were excluded specifically because data suggest the PI3K/AKT pathway is a resistance mechanism to EGFR inhibition.15

In the phase 2 Medical Research Council (MRC) COIN-B trial,16 patients who had metastatic \( \text{KRAS} \) wild-type tumours were treated with an intermittent strategy of oxaliplatin, intravenous fluorouracil, and folinic acid and randomised to either intermittent cetuximab (with intermittent chemotherapy) or continuous cetuximab...
(including single-agent maintenance through the interval between chemotherapy). These trial data showed that use of maintenance cetuximab in the interval was associated with an improvement in the duration of the progression-free interval from 3 months to 6 months. FOCUS4-D builds on these data to test if—in a more specific molecular cohort—AZD8931 will improve progression-free survival in the interval off chemotherapy.

Methods

Patients’ registration and biomarker assessment

We undertook the FOCUS4-D trial at 18 hospital sites in the UK. Patients aged 18 years and older with newly diagnosed locally advanced or metastatic colorectal cancer were eligible for registration in the FOCUS4 trial programme either at the start of a 16-week regimen of first-line chemotherapy or up to 12 weeks into the regimen. Patients could not be registered in FOCUS4 unless a CT scan had been done within 4 weeks of starting chemotherapy (preregistration CT scan). CT scans were obtained at 8 weeks and 16 weeks after chemotherapy was started. A CT scan done at the end of the 16-week regimen was compared with the preregistration CT scan by local radiologists, using Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. Patients whose tumours had progressed were ineligible for randomisation and any further involvement with FOCUS4 ended at this time.

The 16-week duration of first-line chemotherapy was determined by reviewing data from three key trials: COIN, CAIRO3, and AIO0207. This period accounts for factors including maximum tumour response and tolerability by patients. During the 16-week period of first-line chemotherapy, a sample of the patient’s tumour was sent to one of two dedicated FOCUS4 biomarker laboratories in Leeds and Cardiff (UK) for assessment and stratification of the patient into one of four molecular groups. Figure 1 presents the molecular stratification hierarchy for the FOCUS4 trial programme. The technical components of the biomarkers and interlaboratory quality assurance have been described previously.

Patients whose tumours had remained stable or responding to treatment according to CT were assessed for eligibility for FOCUS4-D. The biomarker assessment had to show wild-type status for BRAF, PIK3CA, KRAS, and NRAS, as well as PTEN expression on immunohistochemistry. Figure 2 presents the FOCUS4-D trial design with eligibility criteria. Full inclusion and exclusion criteria are available in the trial protocol, published on the FOCUS4 website. In addition to the eligibility criteria, patients had to have had a minimum 3-week gap between the last dose of chemotherapy or biological therapy and before the first dose of trial drug; a WHO performance status of 0–2; and adequate organ function, ascertained by an estimated creatinine clearance greater than 50 mL/min (according to local estimation method), serum bilirubin less than 1·5× upper limit of normal (ULN), alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase less than 2·5× ULN in the absence of liver metastases and less than 3·0× ULN in presence of liver metastases, and a left-ventricular ejection fraction greater than 50% by multigated acquisition (MUGA) scan or echocardiography.

Ethics approval was granted by the National Research Ethics Service South Central Oxford—Panel C ethics committee (number 13/SC/0111). Regulatory approval was granted by the UK Medicines and Healthcare products Regulatory Agency (clinical trial authorisation [CTA] number 00316/0245/001-0001). All trial procedures and processes complied with the International Conference on Harmonisation’s Good Clinical Practice guidelines. We asked patients to sign a consent form for registration and for analysis of the biomarker panel; additional written informed consent was obtained before randomisation in FOCUS4-D.

Randomisation and masking

Randomisation was done by telephone to a centrally managed service at the MRC Clinical Trials Unit (CTU) at University College London (UCL). Patients were allocated to either AZD8931 or placebo by minimisation...
with a random element of 20% (both patients and clinicians were masked to treatment allocation). Minimisation factors were: treating hospital site, site of primary tumour (right colon, left colon, or rectum), WHO performance status (0, 1, or 2), 16-week CT scan result (stable disease, partial response, or complete response), number of metastatic sites (none, one, or two or more), and first-line chemotherapy regimen (fluorouracil, capecitabine, or neither; both oxaliplatin and irinotecan, oxaliplatin only, irinotecan only, or no monoclonal antibody). AZD8931 and placebo were identical in appearance, and were supplied by or no monoclonal antibody).

**Procedures**

We asked patients to take oral AZD8931 (40 mg twice daily) or placebo until disease progression, death, or toxic effects. We also requested that patients complete a diary card on which the number of pills taken every day was recorded.

We assessed patients every 8 weeks by CT scan, which was reviewed at the treating hospital site according to RECIST, version 1.1. Measurements were collated centrally to ensure appropriate delineation of response and progression. Toxic effects and symptoms were assessed locally every 4 weeks from the start of trial treatment, using the National Cancer Institute's Common Terminology Criteria for Adverse Events (version 3.0). We followed up patients until progressive disease was identified on a CT scan, at which point we recommended the patient should restart first-line chemotherapy.

Treatment was stopped in the event of grade 3 or worse toxic effects or persistent toxicities judged medically significant or not tolerated by the patient, until the toxicity resolved to grade 1 or better. After stopping treatment (for a maximum of 28 days), trial therapy could be re-initiated at a reduced dose. For the first event, treatment was restarted at 40 mg in the morning and 20 mg at night; for the second event, treatment was restarted at 20 mg twice a day. A third event resulted in treatment discontinuation. Any stoppage for 28 days or more was not permitted and the patient was discontinued from trial therapy.

**Outcomes**

The primary outcome of FOCUS4-D was progression-free survival, defined as time from randomisation to either disease progression (according to RECIST criteria) or death from any cause. The trial could be extended to include overall survival as a secondary outcome if adequate drug activity was seen for progression-free survival in the early interim analyses. Additional secondary endpoints included safety, toxicity, and tumour response.

**Statistical analysis**

FOCUS4 uses a multiarm multistage (MAMS) design that allows preplanned analyses to be done to inform a decision on whether to continue the trial. We used the nstage MAMS function in Stata, version 14.1, to calculate the operating characteristics for each molecular trial. For FOCUS4-D we anticipated a recruitment rate of nine patients per month if 100 sites were open. For the placebo group, we assumed a median progression-free survival of 4-6 months, based on a similar group of patients being followed up in the COIN trial. A target hazard ratio (HR) of 0.5 was sought for progression-free survival, with a randomisation ratio of 1:1. Table 1 summarises the operating characteristics for FOCUS4-D, with predicted timelines for the staged interim analyses. Power was maintained at 85% after correction for two interim analyses and one final analysis. Target recruitment was 174 patients, with the first interim analysis timed to occur when nine progression-free survival events had occurred in the control group. At every interim analysis, we compared the observed HR with the critical HR for that interim analysis (table 1). If the HR was above the critical value, trial closure could be considered on the grounds of an absence of sufficient drug activity.

When an interim analysis was triggered by the prespecified number of progression-free survival events in the control group, we cleaned and analysed data and presented the results at a closed and confidential meeting of the independent data monitoring committee (IDMC), who were not involved with conduct of the study. Recommendations to continue or close the study were made to the trial steering committee (TSC), who would recommend their decision. If a decision was made to close the study, the TSC allowed the trial management group (TMG) to see the data to ensure

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Stage 1*</th>
<th>Stage 2†</th>
<th>Stage 3‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>One-sided α</td>
<td>0.5</td>
<td>0.2</td>
<td>0.025</td>
</tr>
<tr>
<td>Power (overall power maintained at 85%)</td>
<td>0.91</td>
<td>0.95</td>
<td>0.95</td>
</tr>
<tr>
<td>Target HR</td>
<td>0.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Critical HR</td>
<td>1.00</td>
<td>0.81</td>
<td>0.70</td>
</tr>
<tr>
<td>Time required (months)</td>
<td>5.9</td>
<td>6.3</td>
<td>7.1</td>
</tr>
<tr>
<td>Cumulative time (months)</td>
<td>5.9</td>
<td>12.3</td>
<td>19.4</td>
</tr>
<tr>
<td>Cumulative events required in placebo group (total events required)</td>
<td>9 (15)</td>
<td>30 (50)</td>
<td>59 (101)</td>
</tr>
<tr>
<td>Total expected cumulative randomisations</td>
<td>54</td>
<td>110</td>
<td>174</td>
</tr>
</tbody>
</table>

HR=hazard ratio. *Safety and lack of sufficient activity. †Lack of sufficient activity.
there were no objections to study closure. When all committees agreed to trial closure, we informed study sites, the pharmaceutical company (AstraZeneca), and the trial funders, and we permitted no further patients entry into the study.

We did all analyses according to a predefined statistical analysis plan that was agreed before any data inspection. The primary outcome was prespecified to be analysed by intention to treat (final analysis). We did interim analyses in the per-protocol sample, which we defined as patients who completed at least one cycle of trial treatment (≥28 days). Per-protocol analyses were done for sensitivity. We analysed data with Stata, version 14.

We censored patients according to the following criteria. For survival status, we censored patients on the date they were last known to be alive, either via collection of prescription from the drug delivery system or attendance at a follow-up visit or CT scan. For patients who died before any follow-up visit or CT scan, we used the date of death as the date of the event and assumed death without progression. For progression-free survival, we censored patients without progression on the date of the last CT scan showing no progression.

We used Kaplan-Meier curves to present survival data and Cox regression modelling to estimate HRs, which we adjusted for the stratification factors that were used to minimise patients into allocated groups. Because the numbers of patients and events were small, we adjusted using the method of inverse probability weighting,23 and using the bootstrap method to estimate CIs. We tested the proportional hazards assumption by regressing scaled Schoenfeld residuals against the log of time.24 If evidence showed significant violation, we did a sensitivity analysis using restricted mean survival analysis.21

The FOCUS4 trial programme is registered at controlled-trials.com, ISRCTN 90061546.

Role of the funding source
The funder had no role in study design, data collection, data analysis, or writing of the report. We informed the funder of results before submission of this Article and offered the funder the opportunity to comment on the data interpretation. DF and LB had access to raw data. RA had final responsibility for the decision to submit for publication.

Results
Between July 7, 2014, and March 7, 2016, 32 patients were randomised (16 into each treatment group) across 18 hospitals in the UK (figure 3). The groups were well balanced in terms of baseline characteristics (table 2). The first interim analysis was triggered in March, 2016, when nine progression-free survival events had occurred in the placebo group. The IDMC reviewed the data as part of a closed confidential meeting and made a recommendation to close the trial based on insufficient drug activity, because the observed HR did not fall below the critical HR threshold of 1·0, which was predefined as part of the multistage sample size calculations (table 1). This decision was subsequently endorsed by both the TSC and TMG. Trial recruitment was closed, and during subsequent follow-up of patients already entered into the study, further progression-free survival events occurred, such that 31 of 32 patients had a
found that the proportional hazards assumption had been violated (Grambsch-Therneau test on log time scale, p=0.25 for intention-to-treat analysis and p=0.35 for per-protocol analysis), but because of the small sample size, a sensitivity analysis using restricted mean survival time analysis at 4 months was done. However, this test did not alter the results for either the intention-to-treat analysis (adjusted restricted mean 2.90 months [95% CI 2.37–3.53] in the placebo group vs 2.95 months [2.37–3.53] in the AZD8931 group; p=0.90 for difference) or the per-protocol analysis (3.08 months [2.61–3.56] vs 3.05 months [2.48–3.63]; p=0.94 for difference).

Among the 32 randomised patients, 11 (34%) received first-line irinotecan and fluorouracil. After progression, only four (36%) of these patients returned to their first-line therapy. Reasons for not doing so were the clinician’s decision because of toxicity or disease progression. A further eight (25%) patients received first-line oxaliplatin plus cetuximab, and four (50%) of these patients returned to this regimen after progression. Reasons for not returning to first-line therapy were patient’s choice (n=4), patient considered for resection (n=1), and reported asymptomatic (n=1) and entering another trial (n=1). A further seven (22%) patients received irinotecan and fluorouracil plus panitumumab as first-line therapy, and only one (14%) patient returned to their first-line regimen after disease progression. The reasons for not returning to first-line therapy were clinician’s decision (toxicity [n=1], progression [n=1], and reported asymptomatic [n=1]) and entering another trial (n=1). A further eight (25%) patients received irinotecan and fluorouracil plus cetuximab or panitumumab as first-line therapy, and only one (14%) patient returned to their first-line regimen after disease progression. The reasons for not returning to first-line therapy were their first-line irinotecan and fluorouracil. After progression, only four (36%) of these patients returned to their first-line therapy. Reasons for not doing so were the clinician’s decision because of toxicity or disease progression. A further eight (25%) patients received first-line oxaliplatin plus cetuximab, and four (50%) of these patients returned to this regimen after progression. Reasons for not returning to first-line therapy were patient’s choice (n=4), patient considered for resection (n=1), and missing data (n=1). Other first-line therapies included oxaliplatin and capcitabine plus bevacizumab (n=2), oxaliplatin and fluorouracil (n=2), capcitabine alone (n=1), and fluorouracil alone (n=1). 11 (34%) of 32 patients restarted their first-line therapy at the time of data collection. No patterns were noted in the reasons given for not restarting therapy. As of November, 2017, not all data for post-progression treatments were available.

Five of 32 patients needed dose reductions; one in the placebo group and four in the AZD8931 group. The patient in the placebo group had their evening dose reduced from 40 mg to 20 mg on their second cycle because of diarrhoea (grade 3). The dose reductions in the AZD8931 group were all evening dose reductions from 40 mg to 20 mg on the second or third cycles and were because of skin rash (grade 2 [n=1] and grade 3 [n=3]). One patient in the AZD8931 group subsequently had a morning dose reduction from 40 mg to 20 mg on their fourth cycle, also because of skin rash (grade 3), and another subsequently had a morning dose reduction from 40 mg to 20 mg on their sixth cycle, for dry eyes (grade 3). All dose reductions were maintained within the currently available data. Only one patient explicitly gave the reason for stopping trial treatment as toxicity. This patient was assigned AZD8931 and reported grade 3 dry eyes, grade 2 skin ulceration, and grade 2 skin rash. No serious adverse events were reported for this patient. Overall, few toxic effects were reported. Adverse events of

---

### Table 2: Baseline characteristics

<table>
<thead>
<tr>
<th></th>
<th>Placebo (n=16)</th>
<th>AZD8931 (n=16)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (years)</strong></td>
<td>64 (58–74)</td>
<td>65 (57–71)</td>
</tr>
<tr>
<td><strong>Sex</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>13 (81%)</td>
<td>13 (81%)</td>
</tr>
<tr>
<td>Female</td>
<td>3 (19%)</td>
<td>3 (19%)</td>
</tr>
<tr>
<td><strong>Current state of primary tumour</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resected primary</td>
<td>11 (69%)</td>
<td>8 (50%)</td>
</tr>
<tr>
<td>Unresected primary</td>
<td>5 (31%)</td>
<td>7 (44%)</td>
</tr>
<tr>
<td>Unresected local recurrence</td>
<td>0 (0%)</td>
<td>1 (6%)</td>
</tr>
<tr>
<td><strong>Timing of metastases</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metachronous</td>
<td>4 (25%)</td>
<td>4 (25%)</td>
</tr>
<tr>
<td>Synchronous</td>
<td>12 (75%)</td>
<td>11 (69%)</td>
</tr>
<tr>
<td>Missing data</td>
<td>0 (0%)</td>
<td>1 (6%)</td>
</tr>
<tr>
<td><strong>Site of primary tumour</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Right colon</td>
<td>5 (31%)</td>
<td>5 (31%)</td>
</tr>
<tr>
<td>Left colon</td>
<td>6 (38%)</td>
<td>6 (38%)</td>
</tr>
<tr>
<td>Rectum</td>
<td>5 (31%)</td>
<td>5 (31%)</td>
</tr>
<tr>
<td><strong>WHO performance status</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>12 (75%)</td>
<td>11 (69%)</td>
</tr>
<tr>
<td>1 or 2</td>
<td>4 (25%)</td>
<td>5 (31%)</td>
</tr>
<tr>
<td><strong>Disease assessment at end of first-line treatment</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Partial response</td>
<td>8 (50%)</td>
<td>7 (44%)</td>
</tr>
<tr>
<td>Stable disease</td>
<td>8 (50%)</td>
<td>9 (56%)</td>
</tr>
<tr>
<td><strong>Number of metastatic sites</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>One</td>
<td>6 (38%)</td>
<td>9 (56%)</td>
</tr>
<tr>
<td>Two or more</td>
<td>10 (63%)</td>
<td>7 (44%)</td>
</tr>
<tr>
<td><strong>Fluoropyrimidine drug used during first-line treatment</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluorouracil</td>
<td>11 (69%)</td>
<td>10 (63%)</td>
</tr>
<tr>
<td>Capecitabine</td>
<td>5 (33%)</td>
<td>6 (38%)</td>
</tr>
<tr>
<td><strong>Oxaliplatin or irinotecan used during first-line treatment</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oxaliplatin only</td>
<td>6 (38%)</td>
<td>6 (38%)</td>
</tr>
<tr>
<td>Irinotecan only</td>
<td>9 (56%)</td>
<td>9 (56%)</td>
</tr>
<tr>
<td>Neither</td>
<td>1 (6%)</td>
<td>1 (6%)</td>
</tr>
<tr>
<td><strong>Monoclonal antibody used during first-line treatment</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cetuximab or panitumumab</td>
<td>4 (25%)</td>
<td>3 (19%)</td>
</tr>
<tr>
<td>Bevacizumab</td>
<td>1 (6%)</td>
<td>1 (6%)</td>
</tr>
<tr>
<td>No antibody</td>
<td>11 (69%)</td>
<td>12 (75%)</td>
</tr>
</tbody>
</table>

Data are number of patients (%) or median (IQR).

---

progression-free survival event by the time of the final analysis on Aug 1, 2016. No patients were lost to follow-up. Median progression-free survival was 3.48 months (95% CI 1.51–5.09) with placebo and 2.96 months (1.94–5.62) with AZD8931 (adjusted HR 1.10, 95% CI 0.47–3.57; p=0.95; figure 4).
grade 1–2 are listed in the appendix. Skin rash was the most frequent grade 3 adverse event, recorded in three (20%) of 15 patients in the AZD8931 group versus no patients in the placebo group; diarrhoea was the most frequent grade 3 adverse event in the placebo group, recorded in one patient (6%) versus one patient (7%) in the AZD8931 group (table 3). No grade 4 adverse events were reported. Five serious adverse events needed admission to hospital, four in the AZD8931 group (epigastric pain [grade 3]; back pain [grade 3], hyperbilirubinaemia [grade 4], and device-related infection [grade 2]; duodenal ulcer [grade 3]; and dehydration [grade 3, but subsequently fatal]) and one in the placebo group (chest infection [grade 3]). No treatment-related deaths were reported. Patients’ compliance was 85% in the placebo group and 75% in the AZD8931 group.

Discussion

The FOCUS4 programme has delivered its first result in a molecularly selected cohort of patients with advanced colorectal cancer. In FOCUS4-D, AZD8931 failed to pass the first stage of assessment within the MAMS trial design—ie, the predefined critical hazard ratio of 1·0 at stage 1 (lack of sufficient activity; table 1) was not reached. However, this trial has set a new paradigm in molecularly stratified trials in colorectal cancer.

Two phase 2, randomised, combination trials of AZD8931 have been done previously, both in patients with breast cancer. The MINT study was stopped because of lack of efficacy (NCT01151215). In this trial, AZD8931 (40 mg or 20 mg twice daily) was compared with placebo in combination with anastrozole in postmenopausal women with hormone receptor-positive locally advanced or metastatic breast cancer who had never had endocrine treatment. The second randomised trial (THYME) did not meet its primary objective of prolonged progression-free survival when AZD8931 was added to weekly paclitaxel in patients with advanced breast cancer and low expression of HER2 (NCT00900627). The primary hypothesis in the THYME study was that low HER2 expression was a driver for heterodimerisation, which would be inhibited by AZD8931. In FOCUS4-D, we were unable to investigate subgroups effectively because of the small sample size. Specific areas of interest include the effect of anti-EGFR agents in the chemotherapy induction phase and pre-randomisation (six patients in total) and the role of primary tumour location as a marker of response to treatment. The findings of these three trials indicate a need for greater understanding of EGFR family heterodimers and their dynamic interaction with targeted agents such as AZD8931.

FOCUS4-D is the first of the FOCUS4 molecular cohorts to reach its first MAMS-defined interim

<table>
<thead>
<tr>
<th>Number at risk (number censored)</th>
<th>Placebo (n=16)</th>
<th>AZD8931 (n=15)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number at risk</td>
<td>16 (0)</td>
<td>16 (0)</td>
</tr>
<tr>
<td>Time since randomisation (months)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>16 (0)</td>
<td>16 (0)</td>
</tr>
<tr>
<td>2</td>
<td>10 (0)</td>
<td>12 (0)</td>
</tr>
<tr>
<td>4</td>
<td>6 (0)</td>
<td>6 (0)</td>
</tr>
<tr>
<td>6</td>
<td>2 (0)</td>
<td>3 (1)</td>
</tr>
<tr>
<td>8</td>
<td>2 (0)</td>
<td>2 (0)</td>
</tr>
<tr>
<td>10</td>
<td>2 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>12</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
</tbody>
</table>

FIGURE 4: PROGRESSION-FREE SURVIVAL (INTENTION-TO-TREAT ANALYSIS)

HR=hazard ratio.

<table>
<thead>
<tr>
<th>Adverse event</th>
<th>Placebo (n=16)</th>
<th>AZD8931 (n=15)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nausea</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Vomiting</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>1 (6%)</td>
<td>1 (7%)</td>
</tr>
<tr>
<td>Stomatitis</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Dry skin</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Skin rash</td>
<td>0</td>
<td>3 (20%)</td>
</tr>
<tr>
<td>Acne</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PPE</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Anaemia</td>
<td>0</td>
<td>1 (7%)</td>
</tr>
<tr>
<td>Neutropenia</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Hyperbilirubinaemia</td>
<td>0</td>
<td>1 (7%)</td>
</tr>
<tr>
<td>Elevated ALT or AST</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Hypomagnesaemia</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Cardiac toxicity</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Pneumonitis</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Infection</td>
<td>0</td>
<td>1 (7%)</td>
</tr>
<tr>
<td>Dry eyes</td>
<td>0</td>
<td>1 (7%)</td>
</tr>
<tr>
<td>Photophobia</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Blurred vision</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Conjunctivitis</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Corneal ulcer</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Fatigue</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Paronychia</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Epistaxis</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Cystitis</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Data are number of patients (%). Adverse events were graded according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events, version 3.0. No grade 4 or 5 events were reported. Adverse events of grade 1–2 are listed in the appendix. ALT=alanine aminotransferase. AST=aspartate aminotransferase. PPE=palmar-plantar erythrodysesthesia.

*Data missing for one patient.

Table 3: Adverse events of grade 3 or worse

See Online for appendix
analysis. The observed HR at the interim analysis was above the critical threshold for continuation of the trial, and the decision to close the trial was clearcut and unanimous across all oversight committees. We see this outcome as a success of the trial design, in that a decision to continue might have wasted clinical trial resources on recruiting and following up a further 142 patients, and closing the trial prevented other patients from being given an ineffective but potentially harmful treatment. FOCUS4-D was designed to detect a target HR of 0·5. Therefore, the probability of a final analysis of 174 patients showing an HR of 0·5 when the noted HR at this interim analysis was 1·10 is exceptionally small.

A limitation of the FOCUS4-D study was that some deviation took place from the assumptions that we made in our sample size calculations. The final sample size is small, with recruitment of only 32 of the maximum expected target of 174 patients. The median progression-free survival in the placebo group was 3·5 months, which is lower than what we had anticipated in our sample size (4·6 months), and the higher event rate brought forward the trigger point for analysis (nine events in the placebo group). Owing to delays in site-opening of this complex trial, recruitment was also slower than anticipated, so this trigger occurred after randomisation of fewer patients than we had expected (32 instead of 54). However, since all but one patient had had a progression-free survival event by the time of the final analysis, we are reassured that further follow-up would not alter the conclusions of the study, and there is little reason to suspect that a further 22 patients (which would take our total sample size to the expected 54 patients at this analysis) would have responded any differently to the 32 patients reported here. Additionally, the fewer patients in the stage 1 analysis of lack of sufficient activity might increase any effect on outcome between the two treatment groups posed by trial imbalances in prognostic factors and choice of first-line treatment. For instance, the trial size makes it impossible to assess with any meaningful interpretation the effects of previous first-line treatment by EGFR inhibition with cetuximab or panitumumab (four patients in the placebo group and three patients in the AZD8931 group).

FOCUS4-D has shown no evidence of efficacy of single-agent EGFR, HER2, and HER3 inhibition with AZD8931 in patients with advanced colorectal cancer whose tumours are wild-type for BRAF, PIK3CA, KRAS, and NRAS after first-line induction therapy. Toxic effects were low, apart from skin rash in about 20% of patients. Early planned interim analyses with prespecified efficacy thresholds for lack of sufficient drug activity might be helpful in closing trials that are very unlikely to show benefit, which could facilitate more efficient use of clinical trial resources. New agents are currently being investigated for testing in this cohort of patients with all wild-type tumours.

Contributors
TM, RK, RW, RA, LB, and DF contributed to study design, RA, EB, SF, LS, JS, MS, KKS, JW, RW, and TM contributed to data collection, LB, DF, RB, SR, PQ, and RA contributed to data analysis. All authors contributed to data interpretation. RA, DF, LB, RK, TM, and RW wrote the report.

Declaration of interests
PQ reports grants from Cancer Research UK, the Experimental Cancer Research Network, the National Institute for Health Research (NIHR), the Efficacy and Mechanism Evaluation programme, the UK Medical Research Council, Roche, Ventana, and Hallo Dx, during the conduct of the study; grants and non-financial support from AstraZeneca and Yorkshire Cancer Research, during the conduct of the study; grants and personal fees from Eisai, outside the submitted work; personal fees from Amgen, outside the submitted work; and support for infrastructure and nursing from the NIHR Clinical Trials Research Network, outside the submitted work. All other authors declare no competing interests.

Acknowledgments
This study was funded by the UK Medical Research Council (MRC) and National Institute for Health Research (NIHR) Efficacy and Mechanism Evaluation programme: Cancer Research UK; NIHR Clinical Trials Research Network; Health and Care Research Wales (and equivalent in devolved nations); and AstraZeneca Drug Supply and Distribution. PQ, MS, and SR received programme grant support from Yorkshire Cancer Research. PQ is an NIHR Senior Investigator at the Department of Pathology Cardiff and Vale University Health Board, All Wales Genetics Laboratories, Wales Cancer Bank. The MRC Clinical Trials Unit at University College London receives funding from the MRC (programme grant MC_UU_12023/20).

References


